Athenex PE Ratio 2016-2021 | ATNX

Current and historical p/e ratio for Athenex (ATNX) from 2016 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Athenex PE ratio as of October 22, 2021 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Athenex PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2021-10-22 2.52 0.00
2021-06-30 4.62 $-1.57 0.00
2021-03-31 4.30 $-1.74 0.00
2020-12-31 11.06 $-1.71 0.00
2020-09-30 12.10 $-1.46 0.00
2020-06-30 13.76 $-1.47 0.00
2020-03-31 7.74 $-1.41 0.00
2019-12-31 15.27 $-1.70 0.00
2019-09-30 12.17 $-1.83 0.00
2019-06-30 19.80 $-2.08 0.00
2019-03-31 12.25 $-2.22 0.00
2018-12-31 12.69 $-1.81 0.00
2018-09-30 15.54 $-1.89 0.00
2018-06-30 18.66 $-1.60 0.00
2018-03-31 17.01 $-1.90 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.275B $0.144B
Athenex, Inc. is a clinical stage biopharmaceutical company. It engaged in the discovery and development of drugs for the treatment of cancer. The company's platform including an Oncology Innovation Platform, a Commercial Platform and a Global Supply Chain Platform. It operates primarily in Buffalo and Clarence, New York, Cranford, New Jersey, Houston, Texas, Chicago, Illinois, Hong Kong and Taipei Taiwan. Athenex, Inc. is based in Buffalo, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76